Global Progressive Supranuclear Palsy Therapeutics Market 2019-2023

進行性核上性麻痺治療の世界市場2019-2023

◆タイトル:Global Progressive Supranuclear Palsy Therapeutics Market 2019-2023
◆商品コード:IRTNTR31276
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年5月16日
◆ページ数:124
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆産業分野:Health Care
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、進行性核上性麻痺治療の世界市場について調査・分析し、市場概要、市場環境、進行性核上性麻痺治療市場規模、製品別(ドーパミン、抗コリン薬、三環式抗抑うつ剤、その他)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・進行性核上性麻痺治療の世界市場概要
・進行性核上性麻痺治療の世界市場環境
・進行性核上性麻痺治療の世界市場動向
・進行性核上性麻痺治療の世界市場規模
・進行性核上性麻痺治療の世界市場:業界構造分析
・進行性核上性麻痺治療の世界市場:製品別(ドーパミン、抗コリン薬、三環式抗抑うつ剤、その他)
・進行性核上性麻痺治療の世界市場:地域別市場規模・分析
・進行性核上性麻痺治療の北米市場規模・予測
・進行性核上性麻痺治療のヨーロッパ・中東・アフリカ市場規模・予測
・進行性核上性麻痺治療のアジア太平洋市場規模・予測
・進行性核上性麻痺治療の主要国分析
・進行性核上性麻痺治療の世界市場:意思決定フレームワーク
・進行性核上性麻痺治療の世界市場:成長要因、課題
・進行性核上性麻痺治療の世界市場:競争環境
・進行性核上性麻痺治療の世界市場:関連企業情報(ベンダー分析)

About this market

The increasing strategic alliances are expected to trigger the progressive supranuclear palsy therapeutics market growth during the forecast period. Vendors in the market are entering into strategic alliances for co-developing and co-commercializing drugs of for licensing the drugs to large pharmaceutical vendors including the academic institutions and several small pharmaceutical vendors lacking the advanced manufacturing processes. Technavio’s analysts have predicted that the progressive supranuclear palsy therapeutics market will register a CAGR of nearly 5% by 2023.

Market Overview

Increasing strategic alliances

The increasing strategic alliances are likely to result in the faster completion of the study leading to the quicker approval of the therapies, thus resulting in the growth of the global progressive supranuclear palsy therapeutics market during the forecast period.

Adverse side effects

The presence of strong adverse side effects of these drugs is currently a major challenge acting as a barrier to the market growth and is expected to remain a challenge to the growth of the global progressive supranuclear palsy therapeutics market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the progressive supranuclear palsy therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated and with the presence of a few market players. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Dopamine – Market size and forecast 2018-2023

Anticholinergic agents – Market size and forecast 2018-2023

Tricyclic antidepressants – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by product

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 14: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

AbbVie Inc.

Acorda Therapeutics Inc.

Biogen Inc.

Bristol-Myers Squibb Co.

Merck & Co. Inc.

PART 15: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 16: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Global progressive supranuclear palsy therapeutics market pipeline: Overview

Exhibit 18: Global progressive supranuclear palsy therapeutics market pipeline: Snapshot

Exhibit 19: Product – Market share 2018-2023 (%)

Exhibit 20: Comparison by product

Exhibit 21: Dopamine – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Dopamine – Year-over-year growth 2019-2023 (%)

Exhibit 23: Anticholinergic agents – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Anticholinergic agents – Year-over-year growth 2019-2023 (%)

Exhibit 25: Tricyclic antidepressants – Market size and forecast 2018-2023 ($ millions)

Exhibit 26: Tricyclic antidepressants – Year-over-year growth 2019-2023 (%)

Exhibit 27: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 28: Others – Year-over-year growth 2019-2023 (%)

Exhibit 29: Market opportunity by product

Exhibit 30: Customer landscape

Exhibit 31: Market share by geography 2018-2023 (%)

Exhibit 32: Geographic comparison

Exhibit 33: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: North America – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in North America

Exhibit 36: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 38: Top 3 countries in Europe

Exhibit 39: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 40: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 41: Top 3 countries in Asia

Exhibit 42: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 43: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 44: Top 3 countries in ROW

Exhibit 45: Key leading countries

Exhibit 46: Market opportunity

Exhibit 47: Global prevalence of geriatric population

Exhibit 48: Impact of drivers and challenges

Exhibit 49: Vendor landscape

Exhibit 50: Landscape disruption

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: AbbVie Inc. – Vendor overview

Exhibit 55: AbbVie Inc. – Business segments

Exhibit 56: AbbVie Inc. – Organizational developments

Exhibit 57: AbbVie Inc. – Geographic focus

Exhibit 58: AbbVie Inc. – Key offerings

Exhibit 59: AbbVie Inc. – Key customers

Exhibit 60: Acorda Therapeutics Inc. – Vendor overview

Exhibit 61: Acorda Therapeutics Inc. – Business segments

Exhibit 62: Acorda Therapeutics Inc. – Organizational developments

Exhibit 63: Acorda Therapeutics Inc. – Key offerings

Exhibit 64: Acorda Therapeutics Inc. – Key customers

Exhibit 65: Biogen Inc. – Vendor overview

Exhibit 66: Biogen Inc. – Business segments

Exhibit 67: Biogen Inc. – Organizational developments

Exhibit 68: Biogen Inc. – Geographic focus

Exhibit 69: Biogen Inc. – Key offerings

Exhibit 70: Biogen Inc. – Key customers

Exhibit 71: Bristol-Myers Squibb Co. – Vendor overview

Exhibit 72: Bristol-Myers Squibb Co. – Business segments

Exhibit 73: Bristol-Myers Squibb Co. – Organizational developments

Exhibit 74: Bristol-Myers Squibb Co. – Geographic focus

Exhibit 75: Bristol-Myers Squibb Co. – Key offerings

Exhibit 76: Bristol-Myers Squibb Co. – Key customers

Exhibit 77: Merck & Co. Inc. – Vendor overview

Exhibit 78: Merck & Co. Inc. – Business segments

Exhibit 79: Merck & Co. Inc. – Organizational developments

Exhibit 80: Merck & Co. Inc. – Geographic focus

Exhibit 81: Merck & Co. Inc. – Segment focus

Exhibit 82: Merck & Co. Inc. – Key offerings

Exhibit 83: Merck & Co. Inc. – Key customers

Exhibit 84: Validation techniques employed for market sizing

Exhibit 85: Definition of market positioning of vendors



【掲載企業】

AbbVie Inc.、Acorda Therapeutics Inc.、Biogen Inc.、Bristol-Myers Squibb Co.、Merck & Co. Inc.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[進行性核上性麻痺治療の世界市場2019-2023]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆